Literature DB >> 1638398

Differential inhibition by NMDA antagonists of rapid tolerance to, and cross-tolerance between, ethanol and chlordiazepoxide.

J M Khanna1, S J Mihic, J Weiner, G Shah, P H Wu, H Kalant.   

Abstract

We have recently found that the non-competitive N-methyl-D-aspartate (NMDA) antagonists, (+)MK-801 and ketamine, block the development of rapid tolerance to ethanol. In the present report we show that they also block rapid cross-tolerance from chlordiazepoxide to ethanol as well as ethanol to chlordiazepoxide. However, NMDA antagonists fail to block the development of rapid tolerance to chlordiazepoxide. Our results suggest that NMDA antagonists may affect not only the acquisition of rapid tolerance or cross-tolerance to sedatives but also the ability to express that tolerance or cross-tolerance, depending on the drugs used. It is also possible that the phenomena of rapid tolerance and rapid cross-tolerance have basic differences not previously reported in the literature.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638398     DOI: 10.1016/0006-8993(92)90824-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Dizocilpine prevents the development of tolerance to ethanol-induced error on a circular maze test.

Authors:  S Rafi-Tari; H Kalant; J F Liu; I Silver; P H Wu
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

2.  Effects of post-ethanol administration of NMDA and non-NMDA receptor antagonists on the development of ethanol tolerance in C57B1 mice.

Authors:  M Karcz-Kubicha; S Liljequist
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 3.  Tolerance to alcohol: A critical yet understudied factor in alcohol addiction.

Authors:  Sophie K Elvig; M Adrienne McGinn; Caroline Smith; Michael A Arends; George F Koob; Leandro F Vendruscolo
Journal:  Pharmacol Biochem Behav       Date:  2021-02-23       Impact factor: 3.533

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.